- Home
- KTB vs ZLAB Comparison
KTB vs ZLAB Comparison
Compare KTB & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KTB | ZLAB |
|---|---|---|
| Founded | 2018 | 2013 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Apparel | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.8B | 2.0B |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | KTB | ZLAB |
|---|---|---|
| Price | $66.87 | $17.76 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 6 |
| Target Price | ★ $96.38 | $57.22 |
| AVG Volume (30 Days) | 638.3K | ★ 806.0K |
| Earning Date | 11-03-2025 | 11-06-2025 |
| Dividend Yield | ★ 3.17% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 3.88 | N/A |
| Revenue | ★ $2,833,659,000.00 | $441,629,000.00 |
| Revenue This Year | $20.46 | $30.20 |
| Revenue Next Year | $11.11 | $34.71 |
| P/E Ratio | $17.22 | ★ N/A |
| Revenue Growth | 9.91 | ★ 24.14 |
| 52 Week Low | $50.00 | $17.75 |
| 52 Week High | $96.80 | $44.34 |
Technical Indicators
Market Signals| Indicator | KTB | ZLAB |
|---|---|---|
| Relative Strength Index (RSI) | 35.32 | 18.27 |
| Support Level | $65.89 | $19.40 |
| Resistance Level | $69.73 | $20.22 |
| Average True Range (ATR) | 2.75 | 0.52 |
| MACD | -0.54 | 0.09 |
| Stochastic Oscillator | 5.41 | 1.83 |
Price Performance
Historical ComparisonAbout KTB Kontoor Brands Inc.
Kontoor Brands Inc is a lifestyle apparel company. It is engaged in designing, manufacturing, sourcing, marketing, and distribution of its portfolio of brands, including Wrangler and Lee. It manufactures its products in owned and leased facilities and distributes the products through both brick-and-mortar and e-commerce retailers. The Company has two reportable segments: Wrangler and Lee. It generates the majority of its revenue from the Wrangler segment. The company's geographical segments are the United States and International, of which the majority of its revenue comes from the United States.
About ZLAB Zai Lab Limited
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-1218 (CCR8) Solid Tumors, ZL-1310 (DLL3 ADC) ES-SCLC Other NECs, ZL-6301 (ROR1 ADC) Solid Tumors, ZL 6201 (LRRC15 ADC) Solid Tumors.